Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trickle Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (1220)	9/24/2002 11:49:20 AM
From: tuck	Respond to of 1784

Hmmm . . . based on the last line in this snipped article, BEC may indeed qualify for Trickle under the 50% trickle revenue rule. I've also harped about the importance of reliable nanoliter dispensing capability, and BEC is in the thick of the industry charge towards that goal. When pharmas start buying this equipment, it might be time buy ACLA. >>FULLERTON, Calif.--(BUSINESS WIRE)--Sept. 24, 2002--Beckman Coulter, Inc., (NYSE:BEC - News) today unveiled plans for a new nanoliter liquid transfer platform to meet growing miniaturization demands from drug discovery, proteomics and genomics markets. Backed by partnerships with a variety of innovative fluidics companies, Beckman Coulter's goal is to deliver a versatile, low-volume liquid handling system for a range of applications in the drug discovery process. The first implementation of Beckman Coulter's nanoliter capabilities will be previewed as the Nanomek(TM) Liquid Transfer Module at the Society for Biomolecular Screening exposition being held September 23 through September 26, 2002 in The Hague, Netherlands. This preview will demonstrate the platform's ability to accurately deliver reagents to several plate formats including 1536-well plates. Initially to extend the Biomek® FX liquid handling capability, Nanomek will be integrated onto the Biomek FX workstation making miniaturization a natural extension of the Biomek FX platform. "As a process driven company, we're dedicated to designing liquid handling systems that will provide intelligent solutions in assay development and high throughput screening, enabling users to reduce overall costs, conserve precious biological material and expand their liquid handling capabilities to realize the benefits of assay miniaturization," said Scott Atkin, vice president/director of Beckman Coulter's Life Science Research Division. "Our flexible instrument design will allow us to expand our portfolio of applications for high throughput screening in drug discovery, as well as genomic and proteomic applications," said Atkin. "This strategy will enable us to capture a large portion of these high growth markets." Beckman Coulter, Inc. is a global biomedical company, headquartered in Fullerton, California. The company develops and markets instruments, chemistries, software and supplies that simplify and automate laboratory processes throughout the biomedical testing continuum. Through pioneering medical research and drug discovery, specialty testing and patient care diagnostics, Beckman Coulter supports all phases of the battle against disease. Annual sales for the company totaled $2 billion in 2001, with 62% of this amount generated by recurring revenue from supplies, test kits and services.<< snip